Clinical Trials Logo

Clinical Trial Summary

The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant recipients.


Clinical Trial Description

The commercial availability of cannabidiol, or CBD oil, has increased in the United Stated and this supplement has the potential to cause a variety of drug-drug interactions, including in solid organ transplant recipients who receive tacrolimus to prevent rejection. Through a series of pharmacokinetic and pharmacodynamics assays, this proposal will identify gene-drug and drug-drug interactions (DDI), including those that place transplant recipients at risk for increased toxicity related to their immunosuppression. The information learned in these studies will help to inform practitioners as to whether cannabidiol needs to be avoided in transplant recipients and how to appropriately adjust doses of CBD and immunosuppression in order to improve health outcomes and long-term treatment success in this high-risk population. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05490511
Study type Interventional
Source Indiana University
Contact Michael Eadon, MD
Phone (317) 274-2502
Email meadon@iupui.edu
Status Recruiting
Phase Phase 1
Start date October 31, 2022
Completion date October 2028

See also
  Status Clinical Trial Phase
Completed NCT03907657 - Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Phase 2
Not yet recruiting NCT06223750 - Virtual Kidney Check and Follow-up N/A
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02238067 - Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis N/A
Completed NCT01194154 - A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA) Phase 2
Completed NCT02263833 - An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice N/A
Active, not recruiting NCT04078750 - PLATO - Medication Adherence in Transplant Recipients N/A
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Completed NCT03189212 - Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation N/A
Enrolling by invitation NCT05374291 - The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD Phase 3
Recruiting NCT05033054 - Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
Completed NCT05064267 - Hemostatic Profiles in Pediatric CKD
Not yet recruiting NCT06069518 - Continuous Glucose Monitoring in Patients With Diabetes on Peritoneal Dialysis
Not yet recruiting NCT03590067 - Oral Findings in a Group of Egyptian Pediatric Patients at Endstage Renal Disease
Recruiting NCT04014127 - Coronary Microvascular Dysfunction in Chronic Kidney Disease
Recruiting NCT04626323 - Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease Phase 2
Not yet recruiting NCT05774392 - An Observational Study of Patients With Chronic Kidney Disease
Not yet recruiting NCT06343727 - A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) N/A
Completed NCT04515797 - QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir Phase 4
Completed NCT03850756 - Early Diagnosis of Kidney Damage Associated With Tobacco Use